Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation

Matthew Arquette, Todd Wasserman, Ramaswamy Govindan, David Garfield, Neil Senzer, Heidi Gillenwater, Mark Socinski

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

For limited-stage small cell lung cancer, twice-daily radiation with concurrent chemotherapy improves survival rate, but has dose-limiting esophageal toxicity. The authors studied 34 patients treated with amifostine in an attempt to decrease the incidence and grade of esophagitis. The results indicate that there was no re duction in toxicity, but the authors were able to maintain the high complete response rate that had been reported previously. These results differ from the use of amifostine in non-small cell lung cancer in which there is the observation of esophageal protection.

Original languageEnglish
Pages (from-to)59-61
Number of pages3
JournalSeminars in Radiation Oncology
Volume12
Issue number1 SUPPL. 1
DOIs
StatePublished - 2002

Fingerprint

Dive into the research topics of 'Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation'. Together they form a unique fingerprint.

Cite this